Prostatic Stories

Benign Prostatic Hyperplasia (BPH) is a common condition that affects many men as they age, particularly those over 50. It occurs when the prostate gland enlarges, pressing against the urethra and leading to uncomfortable urinary symptoms.

The Benign Prostatic Hyperplasia Prostate Treatment Market is poised for a period of stable expansion, driven by key demographic and technological trends. According to a recent market analysis, the market is currently valued at US$33.03 billion in 2024. Looking ahead, the market is expected to exhibit a steady Compound Annual Growth Rate (CAGR) of 3.6%, reaching a projected valuation of US$47.05 billion by 2034.

Prostatic artery embolization (PAE) has emerged as a revolutionary procedure for managing benign prostatic hyperplasia (BPH), offering significant relief to men suffering from urinary symptoms without the need for invasive surgery.